Voyager Therapeutics, Inc. (VYGR) Investor Relations Documents

Voyager Therapeutics, Inc. (VYGR) investor relations documents from the company's IR site: 1 presentation, 11 press releases; latest deck 2026-08-05. Read in-app with summaries. First-party data.

Voyager Therapeutics Corporate Presentation: Voyager Therapeutics' 2026 investment deck highlights two tau-targeting approaches (gene therapy VY1706 and antibody VY7523) for Alzheimer's disease, with key data expected in Q4

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseVoyager Reports Second Quarter 2026 Financial and Operating Results
2026-08-05PresentationVoyager Therapeutics Corporate Presentation
2026-07-13Press releaseVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of
2026-06-29Press releaseVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentati
2026-06-11Press releaseVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
2026-06-01Press releaseVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for A
2026-05-13Press releaseVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinica
2026-05-07Press releaseVoyager Reports First Quarter 2026 Financial and Operating Results
2026-04-27Press releaseVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-
2026-03-09Press releaseVoyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
2026-02-09Press releaseVoyager to Present at Upcoming Investor Conferences
Press releaseSangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disea

VYGR overview · VYGR earnings · VYGR financials · VYGR KPIs · VYGR ownership · VYGR peers · VYGR filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.